- Report
- May 2025
- 187 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1344EUR$1,500USD£1,145GBP
- Report
- May 2025
- 184 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 190 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- August 2024
- 110 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- May 2025
- 184 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 199 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 192 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 478 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 62 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 386 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 149 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- March 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- July 2024
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP

The Selective Estrogen Receptor Modulators (SERMs) market is a subset of the Women's Health market, focusing on the use of SERMs to treat a variety of conditions related to female reproductive health. SERMs are a type of drug that can act as either an agonist or antagonist of the estrogen receptor, depending on the tissue type. This allows them to be used to treat conditions such as endometriosis, uterine fibroids, and menopausal symptoms. SERMs can also be used to reduce the risk of breast cancer and osteoporosis.
SERMs are available in both oral and topical forms, and are often used in combination with other treatments. They are generally considered to be safe and effective, with few side effects.
Some companies in the SERMs market include Pfizer, Novartis, AstraZeneca, and Eli Lilly. Show Less Read more